Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 351
- Registration Number
- NCT06732804
- Locations
- 🇳🇿
CCST, Christchurch, New Zealand
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 748
- Registration Number
- NCT06570772
- Locations
- 🇬🇪
Batumi Referral Hospital/JSC Evex Clinics, Batumi, Georgia
Pilot Study of AVT16 in Healthy Adult Subjects
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 18
- Registration Number
- NCT06400719
- Locations
- 🇳🇿
CCST, Christchurch, New Zealand
Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 35
- Registration Number
- NCT05986786
- Locations
- 🇬🇪
4001, Tbilisi, Georgia
AVT03 With Xgeva in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 208
- Registration Number
- NCT05876949
- Locations
- 🇵🇱
Biokinetica, Józefów, Poland
🇬🇧Richmond Pharmacology, London, United Kingdom
🇿🇦Farmovs, Bloemfontein, South Africa
Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 502
- Registration Number
- NCT05842213
- Locations
- 🇧🇬
Rheumatology clinic, University Multiprofile Hospital for Active Treatment Kaspela, Plovdiv, Bulgaria
A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 336
- Registration Number
- NCT05632211
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
🇳🇿New Zealand Clinical Research, Christchurch, New Zealand
Multicenter Study in Postmenopausal Women with Osteoporosis, ALVOBOND
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 532
- Registration Number
- NCT05395091
- Locations
- 🇬🇪
Investigational Site 9903, Tbilisi, Georgia
🇬🇪Investigational Site 9905, Tbilisi, Georgia
🇵🇱Investigational Site 4810, Zamość, Poland
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
- Conditions
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 413
- Registration Number
- NCT05155293
- Locations
- 🇨🇿
Nemocnicni lekarna Sokolov, Sokolov, Czechia
🇬🇪JSC Evex Medical Corporation, Tbilisi, Georgia
🇱🇻Pauls Stradins Clinical University Hospital SLLC, Riga, Latvia
AVT03 With Prolia in Healthy Male Subjects
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 209
- Registration Number
- NCT05126784
- Locations
- 🇳🇿
NZCR Auckland, Auckland, New Zealand
🇳🇿NZCR Christchurch, Christchurch, Christchuch, New Zealand
🇦🇺Nucleus Network, Herston, Australia